References
1. Kasahara M, Umeshita K, Inomata Y, et al. Long-term outcomes of pediatric living donor liver transplantation in Japan analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society[J]. Am J Transplant 2013;13:1830-1839.
2. Lauro A, Arpinati M, Pinna AD. Managing the challenge of PTLD in liver and bowel transplant recipients[J]. Br J Haematol 2014;169:157-172.
3. Kumarasinghe G, Lavee O, Parker A, et al. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors[J]. J Heart Lung Transplant 2015;34:1406-1414.
4. Martin M, Tilmann S, Uta B, et al. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation[J]. Clin Dev Immunol 2013;(2013):1-14.
5. Jeong HJ, Ahn YH, Park E, et al. Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: Experiences of 20 years in a single center[J]. Korean J Pediatr 2017;60:86-93.
6. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation [J]. Clin Virol 2012;53:186-194.
7. Schubert S, Renner C, Hammer M, et al. Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients[J]. J Heart Lung Transplant 2008;27:0-105.
8. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS guidelines. Br J Haematol 2010;149:675-692.
9. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 2012;13:122-136.
10. Chinnock R, Webber SA, Dipchand AI, et al. A 16-Year multi-institutional study of the role of age and EBV Status on PTLD incidence among pediatric heart transplant recipients[J]. American J Transplant 2012;12:3061-3068.
11. Dolcetti R. B lymphocytes and Epstein–Barr virus: The lesson of post-transplant lymphoproliferative disorders[J]. Autoimmun Rev 2008;7:96-101.
12. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on[J]. Nat Rev Cancer 2004;4:757-768.
13. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease [J]. Rev Med Virol 2008;18:305-319.
14. Kalra A,Roessner C,Jupp J,et al. Epstein-bar virus DNA-emia monitoring for the management of post- transplant lymphoproliferative disorder [J]. Cytotherapy 2018;20:706-714.
15. Kim JM, Lee SK, Kim SJ, et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia[J]. Transplant Proc 2010;42:0-899.
16. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis 2001;3:70-78.
17. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 2012;13:122–136.
18. Fukushima D, Sato K, Kawagishi N, et al. Epstein-Barr virus—associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation[J]. Transplantation 2015;99:114-119.
19. Lu BR, Park KT, Hurwitz M, et al. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation[J]. Transplant Proc 2013;45:301-304.
20. Bakker NA, Verschuuren EAM, Erasmus ME, et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression [J]. Transplantation 2007;83:433-438.
21. Cosmas D, Wimmer, Martin K, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients [J]. Transpl Int 2013;26:999-1006.
22. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation[J]. Crit Rev Oncol Hematol 2005;56:155-167.
23. Chinnock R, Webber SA, Dipchand AI et al. A 16-Year multi-institutional study of the role of age and EBV Status on PTLD incidence among pediatric heart transplant recipients[J]. Am J Transplant 2012;12:3061-3068.
24. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment[J]. Transplantation 2003;75:987-993.
25. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation[J]. Am J Transplant 2008;8:396-403.